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a  b  s  t  r  a  c  t
The diagnosis of cryptococcosis is usually performed based on cultures of tissue or body ﬂu-
ids and isolation of the fungus, but this method may require several days. Direct microscopic
examination, although rapid, is relatively insensitive. Biochemical and immunodiagnostic
rapid tests are also used. However, all of these methods have limitations that may hinder
ﬁnal diagnosis. The increasing incidence of fungal infections has focused attention on tools
for  rapid and accurate diagnosis using molecular biological techniques. Currently, PCR-based
methods, particularly nested, multiplex and real-time PCR, provide both high sensitivity and
speciﬁcity.
In  the present study, we evaluated a nested PCR targeting the gene encoding the ITS-1
and  ITS-2 regions of rDNA in samples from a cohort of patients diagnosed with cryptococ-
cosis. The results showed that in our hands, this Cryptococcus nested PCR assay has 100%speciﬁcity and 100% sensitivity and was able to detect until 2 femtograms of Cryptococcus
DNA.
©  2015 Elsevier Editora Ltda. All rights reserved.
identiﬁed to date, just two closely related species – Cryptococ-ntroductionryptococcosis is a fungal infection caused by encapsu-
ated yeasts of the phylum Basidiomycota,  genus Cryptococcus.
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.Although over 30 different species of Cryptococcus have beenl, Corporación para Investigaciones Biológicas, Carrera 72a No.
cus neoformans and Cryptococcus gattii – cause the majority of
human fungal infections.1–3 Based on speciﬁc polysaccharide
capsule antigen analysis, subtyping data, and comparisons
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of the genomic sequences, pathogenic cryptococci have been
divided into ﬁve capsular serotypes: serotype A (C. neoformans
var. grubii), serotypes B and C (both C. gattii), serotype D (C.
neoformans var. neoformans), and the hybrid diploid serotype
AD.2,4,5
C. neoformans is found worldwide, and it causes the
majority of cryptococcal infections in people with decreased
immunity (primarily AIDS patients, people undergoing immu-
nosuppressive therapies and those with lymphoproliferative
disorders), resulting in varying neurological complications.6
In contrast, C. gattii is principally endemic to tropical and
subtropical regions, and it causes 70% to 80% of cryptococcal
infections in immunocompetent hosts.4,7,8
Although reporting fungal infections is not mandatory in
Colombia, South America, in 2012 Escandón et al. published
the results of a survey on cryptococcosis conducted in Colom-
bia between 2006 and 2010. In this period, 526 reports with at
least one case of cryptococcosis were received. These cases
originated from 72% of the Colombian political divisions. The
most prevalent risk factor reported was HIV infection (83.5%),
with cryptococcosis deﬁning AIDS in 23% of the cases. The
estimated mean annual incidence rate for cryptococcosis in
the general population was one in every 2.4 × 106 habitants,
while in AIDS patients this rate rose to one in 3.3 × 103. Neuro-
cryptococcosis was recorded in 81.8% of the cases. Laboratory
diagnoses were based on direct examination, culture and latex
in 29.3% cases; of 413 Cryptococcus isolates analyzed, 95.6%
were identiﬁed as C. neoformans var. grubii, 1% C. neoformans
var. neoformans, and 3.4% C. gattii.9
Even though the majority of cryptococcosis cases reported
correspond to cryptococcal meningitis, the initial infection
is generally acquired by the inhalation of airborne fungal
propagules from an environmental source.10–12 Both C. neofor-
mans and C. gattii are capable of causing severe pulmonary and
central nervous system (CNS) infections in both immunocom-
petent and immunosuppressed individuals13–15; importantly,
up to 70% of these individuals will die within three months of
infection.16
The diagnosis of cryptococcosis infection is usually based
on isolation of the fungus from cultured tissue or body ﬂu-
ids such as sputum, blood and cerebrospinal ﬂuid, but this
method may require several days to detect and identify the
microorganisms. Although direct microscopic examination is
rapid, this method is relatively insensitive. Of rapid biochem-
ical and immunodiagnostic tests, which can be performed on
blood and/or cerebrospinal ﬂuid,17,18 the detection of crypto-
coccal capsular antigen by latex agglutination is one of the
most helpful tests for fungi performed on a routine basis. Its
ease of use and sensitivity are better than other conventional
immunodiagnostic methods19–21; however, all of these meth-
ods have some limitations that may hinder ﬁnal diagnosis.15
The diagnostic limitations and increasing incidence of
fungal infections have prompted the development of tools
for rapid and accurate diagnosis using molecular biologi-
cal techniques. Currently, molecular methods such as DNA
hybridization and PCR-based methods (particularly nested,
multiplex and real time PCR) provide both high sensitivity and
speciﬁcity. Improvements in PCR techniques have allowed the
detection of minimal amounts of DNA from the C. neoformans
species; in addition, PCR can be used in association with other 1 5;1  9(6):563–570
techniques, making it a valuable tool for molecular epidemi-
ology studies.22–24
Several target sequences have been utilized to identify
the C. neoformans complex, including URA5, CAP59, M13,
and ITS (18S, 5.8S, and 28S). The ITS region of rDNA has
been the most frequently used region for the detection of
fungal sequences because of its high degree of variation
compared to that of other ribosomal DNA regions facilitates
identiﬁcation.25–27
Nested PCR stands out among the most-used PCR-based
techniques for detection and identiﬁcation of C. neoformans
and C. gattii. In this technique, the DNA used in the reaction
is the product of a previous ampliﬁcation, and it is very use-
ful when high sensitivity and speciﬁcity are desirable.28 The
work of Rappelli et al. (1998)26 strongly inﬂuenced this area;
they developed a nested PCR protocol for the detection of C.
neoformans and C. gattii from samples obtained from patients
with neurocryptococcosis. The speciﬁcity and sensitivity of
this technique were tested using DNA from other microorgan-
isms, which were not ampliﬁed. Testing different dilutions of
fungal DNA samples resulted in the ampliﬁcation of up to 10
fungal cells/ml.
Recently, Trilles et al. (2014) developed a hyperbranched
rolling circle ampliﬁcation (HRCA) based on the PLB1 locus.
Used alone and in combination with a semi-nested PCR, this
technique was speciﬁc and highly sensitive. This new method
has great potential for use in direct diagnosis of cryptococcosis
from clinical specimens.29
For the treatment of cryptococcosis, amphotericin B,
ﬂuconazole, and itraconazole are recommended as ﬁrst-
line treatments for C. neoformans and C. gattii infections,
while voriconazole and posaconazole are used as secondary
therapies.30,31 However, worldwide, approximately 625,000
patients living with HIV/AIDS die from cryptococcal menin-
gitis each year (Centers for Disease Control and Prevention,
CDC, Atlanta, USA, http://www.cdc.gov/).
In the present study, we validated the nested PCR described
by Rapelli et al. (1998) in e ITS-1 and ITS-2 coding regions of
C. neoformans/C. gattii. The gold standard diagnostic technique
used in the validation was microorganism culture from clinical
specimens.26 We  aimed at implementing this molecular assay
as an integral component of the diagnostic tests regularly used
in our laboratory.
Materials  and  methods
Clinical  samples  and  isolates
Over the 17-month period from January 2011 to June 2012, 44
human clinical samples from 44 patients with conﬁrmed cryp-
tococcosis were collected. The clinical specimens included:
bronchoalveolar lavage (BAL) (n = 10), bronchial lavage (BL)
(n = 6), biopsy (n = 4), and cerebrospinal ﬂuid (CSF) (n = 24). All of
the specimens were collected at hospitals in Medellín, Colom-
bia, and sent to the Medical and Experimental Mycology Unit
of the Corporación para Investigaciones Biológicas (CIB), for
mycological diagnosis.
To assess the speciﬁcity of the nested PCR, 92 clini-
cal samples collected from patients with other respiratory
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Table 1 – Clinical samples used for the Cryptococcus neoformans/Cryptococcus gattii nested PCR validation.
Kind of patient Type of sample Diagnosis
Clinical samples
(n:187)
Negative controls
(n:51)
Respiratory
symptomatic (n:30)
BAL (n:25)
BL (n:4)
Healthy individuals
(n:21)
Sputum (n:1)
Whole blood (n:21)
Positive controls
(n:44)
Respiratory
symptomatic (n:44)
CSF (n:24) Cryptococcus neoformans (n:44)
BAL (n:10)
BL (n:6)
Biopsies (n:4)
Samples used to
evaluate the
speciﬁcity (n:92)
Respiratory
symptomatic (n:92)
Body ﬂuids (n:4) Aspergillus fumigatus (n:1)
Candida albicans (n:1)
Candida tropicalis (n:2)
Tracheal aspirates (n:9) Aspergillus fumigatus (n:1)
Candida albicans (n:6)
Candida tropicalis (n:1)
Mycobacterium tuberculosis (n:1)
Biopsies (n:25) Aspergillus fumigatus (n:4)
Aspergillus ﬂavus (n:2)
Candida spp. (n:1)
Candida parapsilosis (n:1)
Candida guillermondii (n:1)
Candida albicans (n:3)
Mycobacterium tuberculosis (n:1)
Paracoccidioides brasiliensis (n:7)
Histoplasma capsulatum (n:5)
Sputum (n:20) Aspergillus fumigatus (n:2)
Mycobacterium tuberculosis (n:7)
Paracoccidioides brasiliensis (n:11)
BL (n:10) Aspergillus fumigatus (n:3)
Mycobacterium tuberculosis (n:7)
BAL (n:24) Aspergillus fumigatus (n:4)
Aspergillus ﬂavus (n:1)
Aspergillus versicolor (n:1)
Mycobacterium tuberculosis (n:4)
Paracoccidioides brasiliensis (n:3)
Histoplasma capsulatum (n:5)
Pneumocystis jirovecii (n:6)
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bnfections (diagnosed by culture and/or speciﬁc stains) were
nalyzed. These clinical samples included specimens from
atients diagnosed with: histoplasmosis (n = 10), paracoc-
idioidomycosis (n = 21), pneumocystosis (n = 6), candidiasis
n = 16), aspergillosis (n = 19), and tuberculosis (n = 20). As
egative controls (n = 51), we  used 30 respiratory-negative
amples (by culture and/or speciﬁc stains for cryptococco-
is or other common respiratory infectious pathogens) as
ell as 21 peripheral blood samples from healthy individ-
als (Table 1). Additionally, the nested PCR speciﬁcity was also
valuated, using puriﬁed DNA isolated from cultures of differ-
nt pathogen microorganisms (n = 35), previously identiﬁed by
equencing (Table 2).rocessing  of  clinical  samples
oth respiratory tract specimens (BAL, BL, sputum) and
ody ﬂuids (peritoneal, pleural and CSF) were collectedin 50 ml  sterile Falcon tubes (Becton Dickinson) and cen-
trifuged at 1550 × g for 30 min  (Centra MP4R, IEC). Fresh
tissues (biopsy) were manually homogenized in 3 ml  of ster-
ile saline solution. The pelleted samples and the homogenate
obtained were used for culture and stain, and 0.6 ml  of each
sample was stored at −20◦ C for subsequent DNA extrac-
tion.
Processed specimens were cultured on Sabouraud Dextrose
Agar and Mycosel (Becton Dickinson), incubated at room tem-
perature (±18–22◦ C) for three weeks, and examined weekly
for yeast colonies; the identiﬁcation was performed using
microscopic observation, phenotypic type enzyme (urease
and phenoloxidase), and carbohydrate assimilation patterns
(McTaggart et al., 2011).14 The biovarieties were determined
by culturing the isolates on l-canavanine glycine bromothy-
mol  blue (CGB) selective medium (Klein et al., 2009).32 These
procedures were carried out in a Biosafety Level 3 (BSL3) labo-
ratory.
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Table 2 – Puriﬁed DNA used to evaluate the Cryptococcus
neoformans/Cryptococcus gattii nested PCR speciﬁcity.
Molecular analysis
Microorganisma Strain source Nested PCR for
the complex C.
neoformans/C.
gattii
Aspergillus ﬂavus CIBb −
Aspergillus fumigatus CIB −
Aspergillus terreus CDCc −
Aspergillus niger CDC −
Blastomyces dermatitidis CDC 2008011573 −
Blastomyces dermatitidis ATCC 26199 −
Candida albicans CIB −
Candida guillermondii CIB −
Candida tropicalis CIB −
Candida parapsilosis CIB −
Candida dubliniensis CIB −
Candida glabrata CIB −
Candida krusei CIB −
Candida lusitanae CIB  −
Candida bracariensis CIB  −
Candida ohmeri CIB −
Candida famata CIB −
Candida ortopsilosis CIB −
Candida metapsilosis CIB −
Coccidioides immitis ATCC 28868 −
Cryptococcus neoformans CIB +
Cryptococcus gattii CIB +
Histoplasma capsulatum var.
capsulatum
CDC −
Histoplasma capsulatum var.
capsulatum
G217B −
Histoplasma capsulatum var.
capsulatum
G184B −
Histoplasma capsulatum var.
capsulatum
CDC −
Histoplasma capsulatum var.
duboisii
CDC/5822 −
Histoplasma capsulatum var.
duboisii
CDC/5823 −
Mycobacterium tuberculosis CIB −
Mycobacterium avium CIB −
Paracoccidioides brasiliensis ATCC 60855 −
Paracoccidioides brasiliensis CIB/Pb339 −
Paracoccidioides brasiliensis CIB/Pb18 −
Paracoccidioides lutzii CIB −
Schizophylum commune CIB −
a DNA was isolated from cultures of pathogenic microorganisms (n:
35) previously identiﬁed by nucleic acid sequencing of genomic
targets.
b CIB: Corporación para Investigaciones Biológicas, Medellín,
Colombia.c CDC: Centers for Disease Control and Prevention, Atlanta, USA.
(−) PCR negative result. (+) PCR positive result.
DNA  extraction
Two hundred microliters of each previously processed clini-
cal sample or yeast suspension were used for DNA extraction
®and puriﬁcation. The QIAamp DNA Mini kit (Qiagen, Hilden-
berg, Germany) was used with some modiﬁcations: the initial
incubation with lysis buffer was performed at 65◦ C for one
hour, followed by AL buffer incubation at 90 ◦C for 10 min  and 1 5;1  9(6):563–570
an additional incubation with recombinant lyticase (1UI/l) at
37◦ C for 45 min. For ﬁlamentous fungal isolates, DNA extrac-
tion was performed using the phenol-chloroform method or a
commercial kit with Genomic G-100 columns (Qiagen Inc., CA)
(Sambrook et al., 2001).33 DNA extraction from whole blood
was performed using a protocol described by Einsele et al.
(1997)34 with some modiﬁcations. The relative concentrations
of DNA extracted were determined using a NanoDrop ND2000
(Thermo Scientiﬁc).
C.  neoformans/C.  gattii  nested-PCR  assay
C. neoformans/C. gattii speciﬁc primers that target the gene
encoding the rDNA internal transcribed regions 1 (ITS-1) and
2 (ITS-2) were used in a nested PCR reaction as described by
Rappelli et al. (1998),26 with some modiﬁcations. The master
mix  for the ﬁrst PCR consisted of 10 l of puriﬁed DNA in a
total PCR volume of 50 l with ﬁnal concentrations of 2 mM
MgCl2 (Invitrogen), 0.2 mM of dNTPs Mix, 0.6 M of each outer
and inner primer (Invitrogen) and 0.02 units of Taq polymerase
(Invitrogen). The mixture was incubated at 94 ◦C for 5 min; 20
cycles of 94 ◦C for 45 s, 55 ◦C for 60 s, and 72 ◦C for 1 min; and
a ﬁnal extension at 72 ◦C for 5 min. For the second (nested)
PCR, the mix  was similar to the ﬁrst, except that 2 l of the
ﬁrst PCR product was used as template DNA and the reaction
mixture was incubated at 94 ◦C for 5 min; for 30 cycles of 94 ◦C
for 45 s, 70 ◦C for 60 s, and 72 ◦C for 1 min, with a ﬁnal exten-
sion at 72 ◦C for 5 min. The ﬁnal product of the nested PCR is
an 116 bp fragment that indicates the presence of Cryptococ-
cus DNA in the samples analyzed. As a positive control, 10 l
containing 10 ng of puriﬁed C. neoformans DNA was used in
all PCR assays. To detect any contamination, sterile water was
included in the DNA extraction used as a negative control, and
additional reaction mixtures without DNA were run during all
procedures.
As a control to verify ampliﬁable DNA or to detect the pres-
ence of PCR inhibitors in the clinical samples, a PCR designed
to amplify the human gene for -globin was carried out as
described by Bialek et al. (2005).35 All of the PCR reactions were
run on a Peltier Thermal Cycler PT100 (MJ Research, USA). The
PCR products were visualized by electrophoresis on 2% agarose
gels (Sigma Chemical Co., St. Louis, MO, USA), using gel red
and a UV transilluminator (Molecular Imager® Gel DocTMXR+
BIORAD). All of the nested PCR products were sequenced to
verify that the ampliﬁed DNA fragment corresponded to the
C. neoformans/C. gattii target.
Detection  limit
To establish the detection limit of the nested PCR assay, we
extracted and quantiﬁed DNA from a C. neoformans yeast sus-
pension and performed serial dilutions (1:2) ranging from
40.4 ng to 1 fg. Each of these dilutions was then used for a
speciﬁc PCR, to determine the amount of DNA at the assay’s
detection limit.Data  analysis
The sequences obtained were edited and aligned using
Sequencher software (version 4.8), and homology searches of
b r a z j i n f e c t d i s . 2 0 1 
Table 3 – Nested PCR results obtained on human clinical
samples from patients with cryptococcosis (A) or other
respiratory diseases different from cryptococcosis as
well as healthy individuals taken as controls (B).
Specimen type Proven disease Number of samples
Total Positive
PCR
(A)
Bronco alveolar
lavage
Cryptococcosis 10 10
Bronchial lavage Cryptococcosis 6 6
Biopsy Cryptococcosis 4 4
Cerebrospinal
ﬂuid
Cryptococcosis 24 24
44 44
(B)
Bronco alveolar
lavage
Paracoccidioidomycosis 3 0
Pneumocystis pneumonia 6 0
Histoplasmosis 5 0
Aspergillosis 6 0
Tuberculosis 4 0
Bronchial lavage
No disease 25 0
Aspergillosis 3 0
Tuberculosis 7 0
No disease 4 0
Sputum
Aspergillosis 2 0
Paracoccidioidomycosis 11 0
Tuberculosis 7 0
No disease 1 0
Tracheal aspirate
Aspergillosis 1 0
Candidiasis 7 0
Tuberculosis 1 0
Biopsy
Candidiasis 6 0
Aspergillosis 6 0
Paracoccidioidomycosis 7 0
Tuberculosis 1 0
Histoplasmosis 5 0
Pleural ﬂuid Aspergillosis 1 0
Peritoneal ﬂuid Candidiasis 3 0
Whole blood No disease 21 0
143 0
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both our PCR assays as the gold standard method until a ﬁnal
diagnosis is reached.ll sequences were carried out using the BLASTn program from
he National Center for Biotechnology Information, Washing-
on, DC. The sequences were categorized according to E-values
error probability) as provided by BLASTn, using values lower
han 1 × 1040.
Sensitivity and speciﬁcity for the C. neoformans/C. gattii
ested PCR were calculated using the culture as the gold
tandard, according to the method of Galen and Gambino
1975).36
esults
ross-reaction  assay
one of the DNA isolated from cultures of related microor-
anisms previously identiﬁed by sequencing tested positive
n the Cryptococcus nested PCR assay. By contrast, all puriﬁed5;1 9(6):563–570 567
DNA from the Cryptococcus yeasts, including C. gattii, tested
positive in the nested PCR assay (Table 2).
Detection  of  Cryptococcus  DNA  in  clinical  samples
A total of 44 clinical samples from patients with cryptococ-
cosis that was diagnosed by culture were analyzed through
nested PCR. All of the BL, BAL, biopsies, and CSF samples were
tested positive in the Cryptococcus nested PCR assay. Therefore,
the ITS-1 and ITS-2 of rDNA nested PCR for the Cryptococcus
neoformans/Cryptococcus gattii complex exhibited a sensitivity
of 100% (Table 3A).
To assess the speciﬁcity of this nested PCR assay, 92 clin-
ical samples collected from patients with other diagnosed
respiratory infections by culture and/or speciﬁc stains and
51 negative controls (30 respiratory negative samples and 21
peripheral blood samples from healthy individuals) were ana-
lyzed. The ITS-1 and ITS-2 of rDNA nested PCR exhibited a
speciﬁcity of 100% for the negative controls (0 positives/51
samples) as well as, for those samples (0/92) with other diag-
nosed respiratory infections (Table 3B).
The presence of PCR inhibitors was ruled out because all of
the clinical samples with negative results in the Cryptococcus
PCR assay allowed ampliﬁcation of a speciﬁc fragment of the
human -globin gene.
Detection  limits
DNA extracted from a C. neoformans yeast suspension was
quantiﬁed and serial dilutions (1:2) were performed, ranging
from 40.4 ng to 1 fg. The optimized nested PCR conditions in
our laboratory allowed detection of 2 fg of Cryptococcus DNA
(Fig. 1)
Controls
All of the DNA extraction controls tested negative in the nested
PCR assays. Therefore, any possible cross-contamination dur-
ing the extraction procedure was discarded.
Discussion
In our hands, the Cryptococcus nested PCR assay for rDNA  ITS-1
and ITS-2 of has 100% sensitivity, as it tested positive for all
44 clinical samples (10 BALs, 6 BLs, 4 biopsies and 24 CSFs)
from patients diagnosed with cryptococcosis. The speciﬁcity
of this assay was also 100% as both the 51 negative controls (25
BALs, 4 BLs, 1 sputum, and 21 whole bloods) and the 92 clinical
samples from patients diagnosed with infections other than
cryptococcosis (10 histoplasmosis, 21 paracoccidioidomyco-
sis, 6 pneumocystosis, 16 candidiasis, 19 aspergillosis, and 20
tuberculosis) gave negative results. However, in order to obtain
negative and positive predictive values, a cohort of patients
with syndromes that include C. neoformans/C. gattii as part
of the possible causes will be evaluated in the future usingJust between the years 2006 and 2010 in our country, 526
reports of at least one case of cryptococcosis were obtained in
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116 bp 100 bp
500 bp
1000 bp
M 1 2 3 4 5 6 7 8 M
Fig. 1 – Electrophoresis in agarose gel was running to make evident the detection limit of the Cryptococcus
neoformans/Cryptococcus gattii complex nested PCR. Lanes in gel were loaded with molecular weight marker (M) and
, (3) amplicons from PCR reactions employing (1) 40 ng, (2) 400 pg
DNA.
an epidemiological study conducted by Escandon et al. (2012),
even knowing that the reporting of fungal infections was
not mandatory in Colombia. In microbiology and mycology
laboratories, the diagnosis of fungal infections is based on
direct observation of macro/micro morphological characteris-
tics, culture, or biochemical and serological tests that permit
identiﬁcation of the pathogen.37 Nevertheless, the aforemen-
tioned diagnostic strategies are not always sufﬁcient for
accurate cryptococcosis diagnosis.38 The implementation of
molecular diagnostic tests with high sensitivity and speciﬁcity
would be essential to mycology laboratories in our country.
Early diagnosis that leads to adequate and prompt starting of
antifungal therapy would be crucial in diminishing the sever-
ity of infection.
Accurate diagnosis of infectious fungal diseases is very dif-
ﬁcult because nearly 70 thousand fungal species have been
described. However, only approximately 270 species have been
reported to result in infectious disease in humans, and the
majority of them are not well adapted to growth at human
body temperature (most of these fungi correspond to der-
matophytic species causing superﬁcial infections).39,40 Among
the few species able to produce systemic fungal infections in
humans are those included in the genus Cryptococcus, speciﬁ-
cally C. neoformans and C. gattii.41
In this context, the PCR technique has much strength com-
pared to conventional methods: it is not laborious, can be used
with a small sample, is able to detect a very low fungal load,
and is a very rapid technique.22 Although other genetic tar-
gets, such as the CAP59 gene (involved in Cryptococcus capsule
production) and alternative ribosomal DNA regions (SSU/LSU)
have been used to identify different species of the C. neofor-
mans complex, the high degree of variability of the ITS region
of the rDNA makes it the most commonly used region for
the detection and identiﬁcation of several fungal sequences.
Other studies using different molecular approaches for cryp-
tococcosis diagnosis have also shown high sensitivity and
speciﬁcity.25,28,42–45In our study, speciﬁc primers targeted to the ITS-1 and ITS-
2 regions of rDNA were used according to the description of
Rapelli et al. (1998). Additionally, in order to increase the dis-
ruption efﬁciency and liberate cryptococcal DNA from tissue4 pg, (4) 40 fg, (5) 4 fg, (6) 2 fg, (7) 1 fg, (8) 0 fg of C. neoformans
homogenates, the DNA extraction protocol included an incu-
bation period with recombinant lyticase (1 UI/l) at 37 ◦C for
45 min.
The current gold standard diagnostic test for crypto-
coccosis remains culture, despite its lack of sensitivity.38
Antigen tests are also regularly used to detect cryptococ-
cal antigen (CrAg) by both enzyme immunoassay (EA) or
latex agglutination (LA). These tests are sensitive and speciﬁc
but require expertise, special storage, and a central refer-
ence laboratory.46,47 Additionally, cryptococcal antigen titers
remain high even ﬁve months after effective therapy, which
may lead to false positive test results.48 Recently, a lateral ﬂow
assay (LFA) with the ability to detect CrAg was developed, but
although this rapid test exhibits good sensitivity and speci-
ﬁcity, more  validation studies are necessary.19,49,50
In conclusion, in agreement with the results described by
Rapelli et al. (1998),26 we found that Cryptococcus nested PCR is
a sensitive, speciﬁc, and reproducible method to be used in the
analysis of different clinical samples. We  conﬁrmed the high
sensitivity with the ability to detect amounts down  to 2 fg of
Cryptococcus DNA. This nested PCR assay may be a useful tool
not only for rapid diagnosis of acute cryptococcosis but also for
monitoring patients during therapy and conﬁrming clearance
of the parasite in follow-up exams.
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